Treatment · International
JAMA Psychiatry: efficacy and safety of xanomeline-trospium chloride in schizophrenia
The pivotal randomized trial that supported the first new mechanism of action for schizophrenia in seventy years.
This is the pivotal randomized clinical trial published in JAMA Psychiatry supporting the FDA approval of Cobenfy (xanomeline-trospium chloride) — the first schizophrenia drug in seven decades acting on a non-dopaminergic mechanism.
It is the primary source paper behind much of the lay coverage of the approval.
Read the full JAMA Psychiatry article for the trial design and outcomes.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.
If reading this brought something up for you —
Call or text 988 for the Suicide & Crisis Lifeline. See all crisis resources.